Genome wide study of tardive dyskinesia in schizophrenia.

Translational Psychiatry
Keane LimJ H Lee

Abstract

Tardive dyskinesia (TD) is a severe condition characterized by repetitive involuntary movement of orofacial regions and extremities. Patients treated with antipsychotics typically present with TD symptomatology. Here, we conducted the largest GWAS of TD to date, by meta-analyzing samples of East-Asian, European, and African American ancestry, followed by analyses of biological pathways and polygenic risk with related phenotypes. We identified a novel locus and three suggestive loci, implicating immune-related pathways. Through integrating trans-ethnic fine mapping, we identified putative credible causal variants for three of the loci. Post-hoc analysis revealed that SNPs harbored in TNFRSF1B and CALCOCO1 independently conferred three-fold increase in TD risk, beyond clinical risk factors like Age of onset and Duration of illness to schizophrenia. Further work is necessary to replicate loci that are reported in the study and evaluate the polygenic architecture underlying TD.

References

Dec 21, 2002·The Journal of Biological Chemistry·Mohamed-Ali HakimiRamin Shiekhattar
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanUNKNOWN Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Oct 4, 2005·Proceedings of the National Academy of Sciences of the United States of America·Aravind SubramanianJill P Mesirov
Aug 23, 2006·Expert Opinion on Drug Metabolism & Toxicology·Preeti RamadossGary H Perdew
Mar 12, 2008·Current Opinion in Psychiatry·Christoph U Correll, Eva M Schenk
Mar 19, 2008·Molecular Psychiatry·P F SullivanS L Close
Sep 11, 2008·Pharmacogenomics·Bk ThelmaArun Kumar Tiwari
Nov 1, 2008·Bioinformatics·Andrew D JohnsonPaul I W de Bakker
Jan 15, 2009·Journal of Clinical Psychopharmacology·Siow-Ann ChongDavid Machin
Jan 15, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Aoi SyuTadao Arinami
May 18, 2010·Journal of Clinical Psychopharmacology·Jimmy LeeSiow-Ann Chong
Jul 10, 2010·Bioinformatics·Cristen J WillerGonçalo R Abecasis
Oct 13, 2010·Movement Disorders : Official Journal of the Movement Disorder Society·Lior GreenbaumBernard Lerer
Dec 21, 2010·American Journal of Human Genetics·Jian YangPeter M Visscher
Jan 15, 2011·The FEBS Journal·Petrus J W NaudéUlrich L M Eisel
Jan 27, 2011·The Pharmacogenomics Journal·A K TiwariJ L Kennedy
Aug 3, 2011·The Pharmacogenomics Journal·L GreenbaumB Lerer
Aug 10, 2011·The Pharmacogenomics Journal·S TanakaT Arinami
Sep 13, 2011·International Review of Neurobiology·Heon-Jeong Lee, Seung-Gul Kang
Jun 19, 2012·Nature Genetics·Xiang Zhou, Matthew Stephens
Jul 27, 2012·Translational Psychiatry·S A IvanovaB Wilffert
Dec 12, 2012·The British Journal of Psychiatry : the Journal of Mental Science·Salvador SarróPeter J McKenna
Jun 26, 2013·Nordic Journal of Psychiatry·Woo-Young SonLeen Kim
Sep 11, 2013·Journal of Psychiatric Research·Clement C ZaiJames L Kennedy
Jan 7, 2014·Progress in Neuro-psychopharmacology & Biological Psychiatry·Svetlana A IvanovaAnton J M Loonen
Jan 1, 2015·Bioinformatics·Jack EuesdenPaul F O'Reilly
Jan 20, 2015·Progress in Neuro-psychopharmacology & Biological Psychiatry·Johanna HassStefan Ehrlich
Jan 21, 2015·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Svetlana A IvanovaAnton J M Loonen
Mar 15, 2015·Experimental & Molecular Medicine·Aaron Ciechanover, Yong Tae Kwon
Apr 18, 2015·PLoS Computational Biology·Christiaan A de LeeuwDanielle Posthuma
Jul 21, 2015·American Journal of Human Genetics·Gleb Kichaev, Bogdan Pasaniuc
Feb 2, 2016·Biochemical and Biophysical Research Communications·Peng ChaiBin Liu
Jun 9, 2016·Genome Biology·William McLarenFiona Cunningham
Jul 30, 2016·Pharmacogenomics·Rachel K LanningDaniel J Müller

❮ Previous
Next ❯

Software Mentioned

COJO
STCRP
GCTA
CATIE
MetaXcan
PRSice2
GEMMA
AFR
PAINTOR
ANNOVAR

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here